As ImmusanT initiates the process to develop its treatment regimens for celiac disease and Type 1 diabetes, the company has fast-paced its hiring activity by bringing on board Ken Truitt M.D. Daiichi Sankyo’s SVP for internal medicine therapeutics as its new Chief Medical Officer.
Recently in an annual meeting of ARVO (Association for Research in Vision and Ophthalmology) which had taken place in Hawaii, Sylentis – the pharma company belonging to PharmaMar Group and a pioneer in RNAi research, had presented the positive results from the clinical studies on tivanisiran therapy against dry eye syndrome.
The annual meeting of the American Urological Association had Sesen Bio present its three-month data for its bladder cancer treatment Vicinium. This was Sesen Bio’s first readout following its name change from Eleven Biotherapeutics.
The heart cells are operated by Researchers from University of California San Diego School of Medicine in the US through the simple technique of shining a light and changing its intensity. The growth of the cells is facilitated through a material called graphene converting light into electricity and creating a relatively greater conducive environment than dished made from standard plastic or glass
A research study from the scientists at the National Institutes of Health and the University of Alabama, Birmingham (UAB) discovered that there was a connection between the genes that code for hair color and the genes that signal infection in the body. This study had revealed a reason as to why some people’s hair turn grey in response to an illness.
By getting inspired by dental reconstruction techniques, scientists from KTH Royal Institute of Technology in Sweden reported a new method where acute bone fractures would be treated with a biocompatible adhesive patch providing rigidity of dental resin composites with an extraordinary bonding strength of self-etching primer. The entire procedure would take five minutes to complete.
Holland-based Genesis Innovation Group LLC raised $7.2 million of its $10 million goal toward a fund to invest in early-stage healthcare companies developing medical devices and orthopedic technologies.
Cambridge, Mass.-based Biotech startup Accent Therapeutics announced $40 million A series funding to develop cancer treatment based on epitranscriptomics, an RNA-modifying protein (RMPs) which have been connected to recent cancer studies.
Aimovig, a ground-breaking drug to prevent Migraines was approved by the FDA last week. Aimovig will be the only player in the market to treat migraines. The new drug has to be taken once a month through an injection similar to an insulin shot or an EpiPen.
A research team at the University of Michigan were developing a pill which shows the presence of tumors when exposed to infrared light, and their concept worked well in mice.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.